推荐产品
product name
氯法齐明,
形狀
powder
抗生素活性譜
mycobacteria
作用方式
protein synthesis | interferes
起源
Novartis
SMILES 字串
CC(C)\N=C1/C=C2N(c3ccc(Cl)cc3)c4ccccc4N=C2C=C1Nc5ccc(Cl)cc5
InChI
1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3/b30-24+
InChI 密鑰
WDQPAMHFFCXSNU-BGABXYSRSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
Clofazimine is a riminophenazine, which is used as an antileprosy drug. It is used to treat multidrug-resistant tuberculosis. Clofazimine prevents neutrophil motility and lymphocyte transformation. It has anti-inflammatory effect, which is used to treat discoid lupus erythematosus. Clofazimine has immunosuppressive property.
應用
Clofazimine has been used:
- for antimicrobial preparation
- to study its accumulation on macrophages to form crystal-like drug inclusions (CLDIs)
- to model drug-induced hepatic granulomatous inflammation
- to study the in vivo cargo storage capacity of macrophages
特點和優勢
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
其他客户在看
The Antimicrobial Drugs (2000)
Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis
Lechartier B and Cole ST
Antimicrobial Agents and Chemotherapy, 59(8), 4457-4463 (2015)
Macrophage-mediated clofazimine sequestration is accompanied by a shift in host energy metabolism
Trexel J, et al.
Journal of Pharmaceutical Sciences, 106(4), 1162-1174 (2017)
Sarah Schmidt Grant et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(30), 12147-12152 (2012-07-11)
During Mycobacterium tuberculosis infection, a population of bacteria likely becomes refractory to antibiotic killing in the absence of genotypic resistance, making treatment challenging. We describe an in vitro model capable of yielding a phenotypically antibiotic-tolerant subpopulation of cells, often called
Jakko van Ingen et al.
Antimicrobial agents and chemotherapy, 56(12), 6324-6327 (2012-10-03)
Disease caused by nontuberculous mycobacteria (NTM) is increasing in frequency. The outcome of treatment for NTM lung disease is poor, particularly lung disease caused by Mycobacterium simiae and M. abscessus. Exploring synergy between active available drugs is a sensible way
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门